gene_symbol
UNKNOWN
binding_type
antigen recognition
cytotoxicity
YES
cytotoxicity_type
DIRECT
cytotoxicity_mechanism
TCR recognition of the personalized neoantigen peptide–HLA class II complex on tumor cells activates infused neoantigen-specific T cells, which kill targets via perforin/granzyme release (and potentially Fas–FasL).
enzyme_product
Off
epitope
On
variant
On
isoform
Off
hla_specific
On
gated
Off
other_modifier
CD4+ TCR recognition; HLA-DR/DP/DQ–restricted; patient-specific
trial_id_tar_ref
drug_id_tar_ref
disease_id_tar_ref
nct_id_tar_ref
NCT05908643
disease_id_num_tar_ref
1887
drug_id_num_tar_ref
5023